Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Recurso digital |
| Lingua: | |
| Pubblicazione: |
Zenodo
2025
|
| Soggetti: | |
| Accesso online: | https://doi.org/10.5281/zenodo.17258402 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866902105708560384 |
|---|---|
| author | SOPHIO BRUNJADZE |
| author_facet | SOPHIO BRUNJADZE |
| contents | <p><em><span lang="EN-US">Alzheimer's disease is a type of dementia that affects memory, thinking and behavior. Symptoms eventually grow severe enough to interfere with daily tasks.</span></em></p> <p><em><span lang="EN-US">The treatment will allow people to have more time to participate in daily life and live independently two treatments — <a name="_Hlk206331882"></a>donanemab (Kisunla™) and lecanemab (Leqembi®) — demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer's disease, from the brain reduces cognitive and functional decline in people living with early Alzheimer's. Other treatments can temporarily slow the worsening of dementia symptoms and improve quality of life for those with living Alzheimer's and their caregivers. Today, there is a worldwide effort underway to find better ways to treat the disease, delay its onset and prevent it from developing. is critical to ensure that the person living with dementia receives the best possible care.</span></em></p> <p><em><span lang="EN-US">They work differently by targeting beta-amyloid at different stages of plaque formation, and ultimately these treatments lower beta-amyloid to slow progression of the disease and to reduce clinical decline.</span></em></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17258402 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | ABOUT MODERN DRUGS FOR THE TREATMENT OF ALZHEIMER'S SOPHIO BRUNJADZE Alzheimer's disease, donanemab (Kisunla™) , lecanemab (Leqembi® <p><em><span lang="EN-US">Alzheimer's disease is a type of dementia that affects memory, thinking and behavior. Symptoms eventually grow severe enough to interfere with daily tasks.</span></em></p> <p><em><span lang="EN-US">The treatment will allow people to have more time to participate in daily life and live independently two treatments — <a name="_Hlk206331882"></a>donanemab (Kisunla™) and lecanemab (Leqembi®) — demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer's disease, from the brain reduces cognitive and functional decline in people living with early Alzheimer's. Other treatments can temporarily slow the worsening of dementia symptoms and improve quality of life for those with living Alzheimer's and their caregivers. Today, there is a worldwide effort underway to find better ways to treat the disease, delay its onset and prevent it from developing. is critical to ensure that the person living with dementia receives the best possible care.</span></em></p> <p><em><span lang="EN-US">They work differently by targeting beta-amyloid at different stages of plaque formation, and ultimately these treatments lower beta-amyloid to slow progression of the disease and to reduce clinical decline.</span></em></p> |
| title | ABOUT MODERN DRUGS FOR THE TREATMENT OF ALZHEIMER'S |
| topic | Alzheimer's disease, donanemab (Kisunla™) , lecanemab (Leqembi® |
| url | https://doi.org/10.5281/zenodo.17258402 |